OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Foss on the FDA Approval of Denileukin Diftitox for CTCL

October 31st 2024

Francine Foss, MD, discusses the FDA approval of denileukin diftitox for the treatment of patients with CTCL.

Dr Haggstrom on the Role of Osimertinib in Unresectable EGFR-Mutated NSCLC

October 31st 2024

Daniel E. Haggstrom, MD discusses the role of osimertinib for patients with unresectable EGFR-mutated non-small cell lung cancer.

Dr Badami on a Case Study Illustrating Key Decisions for First-Line Metastatic RCC

October 31st 2024

Ami Umesh Badami, MD, discusses a case study illustrating key decisions in the treatment of metastatic renal cell carcinoma.

Dr Shain on the Evolving Role of Bispecific Antibodies in Multiple Myeloma Management

October 31st 2024

Kenneth Shain, MD, PhD, discusses the evolving role of bispecific antibodies in the management of multiple myeloma.

Dr Rutkowski on the Safety Profile of Avelumab Plus Axitinib in GIST

October 31st 2024

Piotr Rutkowski, MD, discusses the safety and clinical implications of avelumab in combination with axitinib in unresectable or metastatic GIST

Dr Kamdar on the Safety Profile of Liso-Cel Across Patient Subgroups in MCL

October 31st 2024

Manali Kamdar, MD, discusses common toxicities associated with lisocabtagene maraleucel in patients with mantle cell lymphoma.

Dr Sharma on the Clinical Utility of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

October 31st 2024

Janaki Neela Sharma, MD, discusses the FDA approval of enfortumab vedotin plus pembrolizumab for patients with locally advanced/metastatic bladder cancer.

Dr Pabon on the FDA Approval of Zolbetuximab for CLDN18.2+ Gastric/GEJ Adenocarcinoma

October 31st 2024

Cindy Medina Pabon, MD, discusses the clinical relevance of the FDA approval of zolbetuximab for CLDN18.2-positive gastric or GEJ adenocarcinoma.

Dr Spicer on Surgical Considerations After Approval of Perioperative Nivolumab in Resectable NSCLC

October 30th 2024

Jonathan D. Spicer, MD, PhD, FRCS, discusses surgical considerations for patients with for resectable NSCLC after the approval of perioperative nivolumab.

Dr DeAngelo on the Evolving Role of JAK Inhibitors in the Management of Myelofibrosis

October 30th 2024

Daniel DeAngelo, MD, PhD, discusses the evolving role of JAK inhibitors in the management of myelofibrosis and highlights remaining unmet needs for this patient population.

Dr Braunstein on Novel Risk Factors for Veno-Occlusive Disease Development

October 30th 2024

Marc J. Braunstein, MD, PhD, discusses VOD risk factors, management strategies, and prevention strategies in the post-HSCT hematologic malignancy setting.

Dr Sborov on the Use of Ide-Cel and Cilta-Cel in Relapsed/Refractory Multiple Myeloma

October 30th 2024

Douglas W. Sborov, MD, MS, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Dr DeAngelo on the Current Treatment Paradigm for Myelofibrosis

October 30th 2024

Daniel DeAngelo MD, PhD, discusses current treatment strategies for patients with myelofibrosis, highlighting ongoing and recently presented studies

Dr Cosgrove on T-DXd Treatment in Ovarian Cancer

October 30th 2024

Casey M. Cosgrove, MD, discusses treatment with the ADC T-DXd in patients with ovarian cancer.

Dr Badros on the Design of the AURIGA Study of Daratumumab/Lenalidomide in Newly Diagnosed Myeloma

October 30th 2024

Ashraf Z. Badros, MBCHB, discusses the design of the AURIGA trial of daratumumab plus lenalidomide in newly diagnosed myeloma following transplant.

Dr Carthon on Darolutamide Plus ADT in mHSPC

October 29th 2024

Bradley C. Carthon, MD, PhD, discusses treatment with darolutamide and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer

Dr Fisher on the Integration of Bispecific Antibodies and CAR T-cell Therapy into CRS Treatment

October 29th 2024

David C. Fisher, MD, discusses treatment with bispecific antibodies and CAR T-cell therapy, respectively, for patients with cytokine release syndrome.

Dr Tan on the Role of Nivolumab/Ipilimumab in Favorable-Risk Advanced RCC

October 29th 2024

Alan Tan, MD, discusses the potential role of nivolumab plus ipilimumab in favorable-risk renal cell carcinoma

Dr Dhakal on Notable Multiple Myeloma Trials Presented in 2024

October 29th 2024

Binod Dhakal, MD, discusses key trials presented at the 21st International Myeloma Society Annual Meeting in patients with multiple myeloma.

Dr Delforge on the Efficacy of Cilta-Cel in Lenalidomide-Refractory Myeloma

October 29th 2024

Michel Delforge, MD, PhD, discusses the efficacy of cilta-cel in CARTITUDE-4 vs alternative approaches for lenalidomide-refractory myeloma.